{
  "abstract": "Samuel Cross, Karl Claxton, and Andrew Hill argue that diversion of billions of NHS funding to pay more for new drugs under the UK-US trade deal will harm public health and result in thousands of excess deaths",
  "authors": [
    {
      "affiliations": [
        "Christchurch Hospital, Te Whatu Ora, New Zealand"
      ],
      "name": "Samuel Cross"
    },
    {
      "affiliations": [
        "Centre for Health Economics, University of York, York, UK"
      ],
      "name": "Karl Claxton"
    },
    {
      "affiliations": [
        "Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"
      ],
      "name": "Andrew Hill"
    }
  ],
  "title": "Health costs of the UK-US trade deal on pharmaceuticals",
  "uid": "dc64212f-1cef-56da-a8a5-ba83715a8ec0"
}